{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-008807","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.096956+00:00","generated_at":"2026-06-06T14:26:11.944814+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Regeneron appoints Christopher Fenimore as CFO to succeed retiring Robert Landry","bullets":["Christopher Fenimore promoted to SVP, Finance and CFO; effective day after 2023 10-K filing (expected Feb 5, 2024).","Jason Pitofsky promoted to VP, Controller; no change in compensation.","Fenimore's base salary increased to $660,000; granted equity award with target fair value of $5,000,000.","Equity award includes options for 8,499 shares (4-year vest) and 2,370 RSUs (50% at years 2 and 4).","Succession plan previously disclosed; Landry retiring."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-008807","json":"https://secwatch.observer/filing/0001104659-24-008807.json","markdown":"https://secwatch.observer/filing/0001104659-24-008807.md","text":"https://secwatch.observer/filing/0001104659-24-008807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/0001104659-24-008807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/tm244671d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:26:11.944814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14f80ada03","claim":"Robert E. Landry departed as Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"the current Chief Financial Officer, Robert E. Landry, who is retiring.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/0001104659-24-008807-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retiring"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"16621e6536","claim":"Christopher Fenimore was appointed as Senior Vice President, Finance and Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"appointed Christopher Fenimore, currently the Company’s Senior Vice President, Controller, as Senior Vice President, Finance and Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/0001104659-24-008807-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Finance and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"31c4e9924b","claim":"Jason Pitofsky was appointed as Vice President, Controller at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"appointed Jason Pitofsky, currently the Company’s Vice President, Accounting and Financial Reporting, as Vice President, Controller.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/0001104659-24-008807-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice President, Controller"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}